Very useful, thank you Saltland.
Veritas report suggests that Remplir is both more flexible, and more resorbable, than at least Integra and Axogen products, with flow on patient benefits. (Stryker product ranking unclear).
If we look forward to the time at which OCC assumes Remplir achieves 20% global market share, and market leadership, it is difficult to comprehend what the other (lesser) market shares might be.
If suturing, Axogen, Stryker and Integra are all less than 20%, it makes me think the Remplir result is wholly conservative. That is, if it is superior to all known alternatives today, a higher market share should be achievable within 4 or 5 years, absent a blockbuster new product.
Much to digest.
Very useful, thank you Saltland.Veritas report suggests that...
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.005(1.27%) |
Mkt cap ! $81.63M | |||
| Open | High | Low | Value | Volume |
| 39.5¢ | 39.5¢ | 38.5¢ | $29.16K | 75.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 75123 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 37896 | 2 |
View Market Depth
| Last trade - 14.32pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
39.0¢ |
Change
-0.005 ( 1.27 %) |
||||
| Open | High | Low | Volume | ||
| 38.5¢ | 39.0¢ | 38.5¢ | 25594 | ||
| Last updated 14.32pm 06/05/2024 ? | |||||
| OCC (ASX) Chart |